On June 26, 2025, CRISPR Therapeutics AG announced updates on its cardiovascular disease programs, highlighting promising results from its CTX310 clinical trial, which achieved peak reductions of up to 82% in triglycerides and 86% in LDL cholesterol without significant safety concerns.